Phase I Trial of Concurrent Twice-Weekly Recombinant Human Interleukin-12 Plus Low-Dose IL-2 in Patients With Melanoma or Renal Cell Carcinoma Purpose: Response of solid malignancies to therapy is ...
Lisbeth Cordero Méndez, IAEA Department of Nuclear Sciences and Applications Research involving 23 countries has highlighted the safety and benefit of using artificial intelligence for a key and often ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback